Biotech

All Articles

AN 2 halves census, quits stage 3 trial after information let down

.AN2 Therapies is actually reviewing its business in response to uninspired midphase data, vowing to...

Merck pays $700M for bispecific, snooping autoimmune position and also odds to challenge Amgen in cancer cells

.Merck &amp Co. is spending $700 million in advance to test Amgen in a blood cancer market. The barg...

Gilead pays J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences almost an FDA selection for its liver ailment medicine seladelpar, the provide...

' All palms on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can observe the companies putting together camping tents at bas...

Entero giving up workers, vacating workplace and also stopping briefly R&ampD

.Bed Liquidators has actually switched Entero Therapies white colored as a sheet. The lender got Ent...

Exelixis goes down ADC after choosing it's no suit for Tivdak

.Exelixis is losing hope on its own cells factor (TF)- targeting antibody-drug conjugate after wrapp...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.Three weeks after Roche's Genentech unit ignored an SHP2 inhibitor pact, Relay Rehab has actually v...

Stoke's Dravet syndrome med launched of predisposed scientific grip

.Stoke Therapies' Dravet disorder drug has actually been actually devoid of a partial hold, getting ...

Fierce Biotech's Gabrielle Masson offers Brutal 15 at NYSE

.Fierce Biotech Affiliate Editor Gabrielle Masson provided the 2024 course of Intense 15 victors on ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has actually axed its once-monthly dual GLP-1/ GIP receptor agonist, ending (PDF) prog...